Gapping up:Earnings: GOGO +5.3%, LUK +3.0%.
General news:
- LJPC +40.2% (announces positive top-line results from athos-3 phase 3 study of LJPC-501; 'primary efficacy endpoint analysis highly statistically significant'),
- PIRS +17.2% (granted ASKA Pharma an exclusive option to license development and commercial rights to Pieris' anemia drug, PRS-080, in Japan and certain other Asian markets following completion of a multi-dose Phase 2a study; co will receive an immediate option payment of $2.75 mln from ASKA),
- ATRS +12.0% (announces that the New Drug Application for QuickShot Testosterone has been accepted for standard review by the FDA),
- ACRX +8.3% (New Drug Application for DSUVIA accepted for filing; PDUFA date is October 12, 2017),
- FEYE +2.3% (still checking)
Analyst actions:
- PTEN +3.4% (added to US 1 List at BofA/Merrill),